Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
24.07.2026 11:10
Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
24.07.2026 10:26
FOSTER CITY, Calif., July 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received pri
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer
24.07.2026 06:29
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing
Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions
16.07.2026 17:00
Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
16.07.2026 13:00
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
15.07.2026 13:10
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
12.07.2026 13:43
Gilead's expansion beyond HIV therapies will surprise many investors.
2 Recession-Resistant Dividend Stocks to Buy and Hold
10.07.2026 16:20
You don't need to predict a recession to prepare your portfolio. These two stocks can help.
Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access
09.07.2026 07:12
Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative
09.07.2026 06:11
Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...
BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients
07.07.2026 14:00
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. BBG Advanced Therapies labs and offices BBG Advanced Therapies, a subsidiary
Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
07.07.2026 13:00
– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at Seagen, CytomX, Gilead and Merus – CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the appointment of Roland Gendron as Chief Business Offi
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
06.07.2026 18:36
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
06.07.2026 08:58
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155
06.07.2026 05:51
HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.
Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?
05.07.2026 12:59
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
27.06.2026 04:15
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
27.06.2026 03:10
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
26.06.2026 14:45
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.